Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mondaycom Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Mondaycom Ltd trades at $83.28 (market cap $3.54B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.3× Mondaycom Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | MNDY | |
|---|---|---|
Market Cap | $39.89B | $3.54B |
Sector | Health | Technology |
52-Week High | $491.22 | $292.24 |
52-Week Low | $278.09 | $58.81 |
Enterprise Value | $38.15B | $2.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Monday.com (MNDY) trades at $82.47, down 1.41% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $116.75. The company reported strong revenue of $1.23 billion in 2025 and has beaten EPS estimates for three consecutive quarters, though its EV/EBITDA of 110.73 indicates high valuation expectations. Recent news highlights investor interest despite stock volatility, with the Motley Fool noting the dip may present a buying opportunity.
The outlook for MNDY is positive based on analyst sentiment and earnings performance, but risks include elevated valuation multiples and competitive pressures in the SaaS sector. Investors should weigh the company's robust growth against potential market volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
